Alnylam
Manufacturing · France · 51-200 Employees
View Company Info for Free
Overview
Headquarters
100-102 Avenue De Suffren, Paris, Ile-de...Website
www.alnylam.frRevenue
$34 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Alnylam
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam's commercial RNAi therapeutic products are ONPATTRO® (patisiran), GIVLAARI® (givosiran), OXLUMO® (lumasiran), and Leqvio® (inclisiran) being developed and commercialized by Alnylam's partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its "Alnylam P5x25" stratRead more
Popular SearchesAlnylamSIC Code 28,283NAICS Code 32,325Show moreAlnylam Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Alnylam your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Alnylam launches new products
Congratulate Masked Content for being promoted to Masked Content at Alnylam
Alnylam, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Alnylam had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Alnylam has new funding data
Check out if Alnylam is spiking on competitors!
Check if Alnylam has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Alnylam recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Alnylam as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Alnylam is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Alnylam is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Alnylam.
Alnylam Tech Stack
A closer look at the technologies used by Alnylam
Alnylam News & Media
Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company’s possible violations of federal securities laws.Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES, Aug. 19, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) on behalf of investors concerning the Company’s possible violations of federal securities laws.Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Continuing Securities Fraud Investigation
BENSALEM, Pa., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) investors concerning the Company’s possible violations of federal securities laws.Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES, Aug. 12, 2026 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz continues its investigation of Alnylam Pharmaceuticals, Inc. (“Alnylam” or the “Company”) (NASDAQ: ALNY) on behalf of investors concerning the Company’s possible violations of federal securities laws.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Alnylam
Sign Up For FreeTo access detailed company insights
Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics r... Read More
